Drug Profile
Mesothelin CAR-T cell therapy - Novartis/University of Pennsylvania
Alternative Names: CART-mesoLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Novartis; University of Pennsylvania
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mesothelioma; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Mesothelioma(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Ovarian-cancer(Late-stage disease, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Pancreatic-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)